These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30694080)

  • 1. Patient preferences for treatment of metastatic melanoma.
    Mansfield C; Ndife B; Chen J; Gallaher K; Ghate S
    Future Oncol; 2019 Apr; 15(11):1255-1268. PubMed ID: 30694080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.
    Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Basurto E; Joseph RW
    Cancer Nurs; 2019; 42(1):E52-E59. PubMed ID: 29076867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.
    Marshall T; Pugh A; Fairchild A; Hass S
    Value Health; 2017 Dec; 20(10):1383-1393. PubMed ID: 29241898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
    Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
    Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient preferences for treating refractory overactive bladder in the UK.
    Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
    Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients prioritize local recurrence risk over other attributes for surgical treatment of facial melanomas-Results of a stated preference survey and choice-based conjoint analysis.
    Etzkorn JR; Tuttle SD; Lim I; Feit EM; Sobanko JF; Shin TM; Neal DE; Miller CJ
    J Am Acad Dermatol; 2018 Aug; 79(2):210-219.e3. PubMed ID: 29505861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodialysis patients' preferences for the management of anemia.
    Hauber B; Caloyeras J; Posner J; Brommage D; Tzivelekis S; Pollock A
    BMC Nephrol; 2017 Jul; 18(1):253. PubMed ID: 28750609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of information on preferences for treatments of metastatic renal cell carcinoma.
    Mansfield C; Srinivas S; Chen C; Hauber AB; Hariharan S; Matczak E; Sandin R
    Curr Med Res Opin; 2016 Nov; 32(11):1827-1838. PubMed ID: 27404275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing of New and Old Therapies for Metastatic Melanoma.
    Ratterman M; Hallmeyer S; Richards J
    Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preferences for diabetes treatment attributes and drug classes.
    Flood EM; Bell KF; de la Cruz MC; Ginchereau-Sowell FM
    Curr Med Res Opin; 2017 Feb; 33(2):261-268. PubMed ID: 27779433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parental preferences for vesicoureteral reflux treatment: Profile case best-worst scaling.
    Dionise ZR; Gonzalez JM; Garcia-Roig ML; Kirsch AJ; Scales CD; Wiener JS; Purves JT; Routh JC
    J Pediatr Urol; 2021 Feb; 17(1):86.e1-86.e9. PubMed ID: 33309608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
    Leccia MT; Planchamp F; Sassolas B; Combemale P; Modiano P; Bedane C; Cupissol D; Derrey S; Dygai-Cochet I; Lamant L; Lubrano V; Mirabel X; Mourrégot A; Rougé Bugat ME; Siegrist S; Thariat J; Tiffet O; Truc G; Verdoni L; Mazeau-Woynar V
    Ann Dermatol Venereol; 2014 Feb; 141(2):111-21. PubMed ID: 24507205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and quantification of treatment preferences for patients with asthma or COPD using discrete choice experiment surveys.
    Svedsater H; Leather D; Robinson T; Doll H; Nafees B; Bradshaw L
    Respir Med; 2017 Nov; 132():76-83. PubMed ID: 29229109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of preferences of targeted therapy for metastatic renal cell carcinoma between the patient group and health care professional group in South Korea.
    Park MH; Jo C; Bae EY; Lee EK
    Value Health; 2012; 15(6):933-9. PubMed ID: 22999144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australian Public Preferences for the Funding of New Health Technologies: A Comparison of Discrete Choice and Profile Case Best-Worst Scaling Methods.
    Whitty JA; Ratcliffe J; Chen G; Scuffham PA
    Med Decis Making; 2014 Jul; 34(5):638-54. PubMed ID: 24713695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastasectomy for Stage IV Melanoma in the Era of Effective Systemic Agents.
    Ollila DW; Lopez NE; Hsueh EC
    Crit Rev Oncog; 2016; 21(1-2):37-55. PubMed ID: 27481001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Preferences for Endometriosis Pain Treatments in the United States.
    Poulos C; Soliman AM; Renz CL; Posner J; Agarwal SK
    Value Health; 2019 Jun; 22(6):728-738. PubMed ID: 31198191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer survivors' preference for follow-up care providers: a cross-sectional study from the population-based PROFILES-registry.
    Huibertse LJ; van Eenbergen M; de Rooij BH; Bastiaens MT; Fossion LM; de la Fuente RB; Kil PJ; Koldewijn EL; Meier AH; Mommers RJ; Niemer AQ; Oddens JR; Oomens EH; Prins M; de Roos KP; Thissen MR; Timmermans MW; Wijsman BP; van de Poll-Franse LV; Ezendam NP
    Acta Oncol; 2017 Feb; 56(2):278-287. PubMed ID: 28068157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.